Possible patent challenge to Biogen's Tysabri
FiercePharma noted of Biogen's prospects:
India’s Swiss Pharma International has filed a petition for inter partes review of one of Tysabri’s patents--and another two petitions are on the way, Leerink Partners analyst Geoffrey Porges wrote in a note to clients on Monday. The move could potentially put sales of the drug, which tallied $1.89 billion in 2015, in jeopardy, he noted.
link: http://www.fiercepharma.com/pharma/ms-patent-challenges-put-billions-biogen-sales-at-risk
India’s Swiss Pharma International has filed a petition for inter partes review of one of Tysabri’s patents--and another two petitions are on the way, Leerink Partners analyst Geoffrey Porges wrote in a note to clients on Monday. The move could potentially put sales of the drug, which tallied $1.89 billion in 2015, in jeopardy, he noted.
link: http://www.fiercepharma.com/pharma/ms-patent-challenges-put-billions-biogen-sales-at-risk
posted by Lawrence B. Ebert at 5:51 AM
0 Comments:
Post a Comment
<< Home